| Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165 ST Wrobleski, R Moslin, S Lin, Y Zhang, S Spergel, J Kempson, ... Journal of Medicinal Chemistry 62 (20), 8973-8995, 2019 | 257 | 2019 |
| Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of … R Moslin, Y Zhang, ST Wrobleski, S Lin, M Mertzman, S Spergel, ... Journal of Medicinal Chemistry 62 (20), 8953-8972, 2019 | 66 | 2019 |
| Altered xanthine oxidase and N‐acetyltransferase activity in obese children MS Chiney, SJ Schwarzenberg, LAA Johnson British journal of clinical pharmacology 72 (1), 109-115, 2011 | 54 | 2011 |
| Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2 C Liu, J Lin, C Langevine, D Smith, J Li, JS Tokarski, J Khan, M Ruzanov, ... Journal of Medicinal Chemistry 64 (1), 677-694, 2020 | 45 | 2020 |
| Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin MS Chiney, RM Menon, OF Bueno, B Tong, AH Salem Xenobiotica 48 (9), 904-910, 2018 | 31 | 2018 |
| Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621 EC Mark J. Ratain, Toshihiko Doi, Maja J. De Jonge, Patricia LoRusso, Martin ... American Society of Clinical Oncology 37 (15_Supplmental), 3013, 2019 | 19* | 2019 |
| Quantitative assessment of elagolix enzyme-transporter interplay and drug–drug interactions using physiologically based pharmacokinetic modeling MS Chiney, J Ng, JP Gibbs, M Shebley Clinical Pharmacokinetics 59 (5), 617-627, 2020 | 18 | 2020 |
| Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis J Krupinski, N Morgan, A Kozhich, M Chiney, P Morin, R Christian Hepatology 63 (1 SUPP), 749A-749A, 2016 | 12 | 2016 |
| Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology J Weddell, MS Chiney, S Bhatnagar, JP Gibbs, M Shebley Clinical and translational science 14 (1), 395-404, 2021 | 11 | 2021 |
| Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping KI Balkrishna D. Swar, Manoj Chiney, Abbas Rupawala, Shital R. Bendkhale ... Indian Journal of Pharmacology 48 (3), 248–251, 2016 | 5 | 2016 |
| Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure D Mukherjee, MS Chiney, X Shao, TR Ju, M Shebley, P Marroum Biopharmaceutics & Drug Disposition 43 (3), 98-107, 2022 | 4 | 2022 |
| First-in-Human safety, pharmacokinetic and pharmacodynamic study of escalating single-and multiple-doses of bms-986256, a novel, potent, oral inhibitor of TLR7 and TLR8 M Harrison, M Chiney, D Shevell, L Dong, M Dawes, I Girgis ARTHRITIS & RHEUMATOLOGY 73, 3690-3691, 2021 | 2 | 2021 |
| First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: dose-optimization cohorts E Calvo, MJA de Jonge, DW Rasco, V Moreno, YW Chang, M Chiney, ... Annals of Oncology 30, v169-v170, 2019 | 2 | 2019 |
| Bms-986256, an oral novel Toll-like receptor 7 and 8 (TLR7/8) inhibitor, does not affect the pharmacokinetics of mycophenolate mofetil in healthy subjects M Chiney, I Girgis, M Harrison, X Zhang, Y Shen, M Dawes, L Dong, ... ARTHRITIS & RHEUMATOLOGY 73, 3686-3688, 2021 | 1 | 2021 |
| PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS) Manoj Chiney, AR Polepally, AM Nader, MB Dufek, CE Klein, JW Ng, M Shebley CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (S 1), S59-S59, 2017 | 1 | 2017 |
| Discovery of a pseudokinase domain ligand as an allosteric inhibitor of TYK2 for the treatment of autoimmune diseases D Weinstein, S Wrobleski, R Moslin, S Lin, Y Zhang, S Spergel, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 252, 2016 | 1 | 2016 |
| LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric … T Ide, M Chiney, HYT Bach, V Goti, B Murthy, C Hobar, Q Zhao, U Aras Lupus Science & Medicine 10 (Suppl 1), 2023 | | 2023 |
| AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC … T Ide, M Chiney, HYT Bach, V Goti, B Murthy, C Hobar, Q Zhao, U Aras Annals of the Rheumatic Diseases 82 (Suppl 1), 1452-1453, 2023 | | 2023 |
| POS1129 IN VITRO EVIDENCE DEMONSTRATES THAT AFIMETORAN (BMS-986256), AN EQUIPOTENT TLR7/8 DUAL ANTAGONIST, HAS STEROID-SPARING POTENTIAL IN THE CLINIC Q Zhao, A Dyckman, G Schieven, H Qiu, R Zhang, ME Cvijic, M Harrison, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 892-892, 2023 | | 2023 |
| BMS-986256, AN ORAL NOVEL TOLL-LIKE RECEPTOR 7 AND 8 (TLR7/8) INHIBITOR, IS NOT A SENSITIVE SUBSTRATE OF CYTOCHROME P450 3A4: CLINICAL EVALUATION WITH ITRACONAZOLE. M Chiney, I Girgis, M Harrison, X Zhang, Y Shen, M Dawes, U Aras, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S14-S15, 2022 | | 2022 |
